Regeneron Archives

News and Trends 4 Jun 2020

Update: Fifth US Antibody Patent Owned by UK Biotech Upheld in Regeneron Battle

Update (04/06/2020): After upholding four of Kymab’s patents addressing the production of antibody drugs earlier this year, the US Patent Trial and Appeal Board has rejected Regeneron’s attempt to invalidate a fifth patent regarding the same technology. So far, Regeneron has not requested a re-hearing from the Board regarding the decision to uphold Kymab’s first […]

June 4, 2020 - 4 minutesmins - By Anita Chakraverty

News and Trends 4 Nov 2019

Finnish Genetics Study Provides Clues for Treating Type 2 Diabetes

A genetic mutation common to Finnish populations has been found to protect against type 2 diabetes by increasing insulin in the blood, providing a potential target for new drugs. The mutation is found in at least 0.2% of the population in western Finland, whereas it only appears in 0.02% of other European populations. The mutation […]

November 4, 2019 - 2 minutesmins - By Jonathan Smith

hpv cancer isa pharmaceuticals regeneron

News and Trends 18 Dec 2017

Dutch and US Biotechs Team Up Against HPV-related Cancer

ISA Pharmaceuticals will work together with Regeneron to combine its immunotherapy against cancer induced by HPV infection with its partner’s PD-1 checkpoint inhibitor. The human papillomavirus (HPV) is known for its ability to cause cancer, including cervical and head and neck cancer. Based in Leiden, the Netherlands, ISA Pharmaceuticals’ target choice is type 16 HPV, which […]

December 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Dec 2017

Biotech and Pharma Giants Make a Good Start to Phase II Trial for Skin Cancer

Regeneron and Sanofi have announced positive early results from a Phase II study investigating their skin cancer antibody, cemiplimab. Despite deciding to end their antibody partnership at the end of the year, Regeneron and Sanofi are still committed to pushing through a number of candidates. One of these, cemiplimab, is a programmed cell death protein-1 (PD-1) checkpoint […]

December 13, 2017 - 3 minutesmins - By Alex Dale

News and Trends 2 Oct 2017

Update: The EU Approval of Dupixent Might Bring its Pricing Polemic to Europe

Update (01/10/2017): The European Commission has tighter control over pricing that governments have over here Images via Tero Vesalainen, Roman Stetsyk /Shutterstock

October 2, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 8 Sep 2017

Checkpoint Inhibitor from Regeneron and Sanofi gets Priority After Breakup

The FDA has granted breakthrough therapy designation to Regeneron and Sanofi for cemiplimab, just a month after announcing they will part ways soon. Cemiplimab (REGN2810) has been granted breakthrough therapy designation by the FDA for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC), considered the second deadliest skin cancer after melanoma. The antibody is a […]

September 8, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 20 Jun 2017

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

Bayer’s and Regeneron’s blockbuster Eylea could be facing serious competition, as Novartis boasts with positive Phase III results for AMD. Novartis has been struggling on the age-related macular degeneration (AMD) market since its Roche-partnered VEGF-A inhibitor Lucentis was outperformed by Eylea from Bayer and Regeneron, which required a less-frequent dosing schedule and was placed at a lower […]

June 20, 2017 - 2 minutesmins - By Melanie De Almeida

Regeneron Sanofi dupilumab Atopic Dermatitis

News and Trends 29 Mar 2017

Get Ready for One of the Biggest New Drug Approvals of the Year

After Praluent, Sanofi and Regeneron have now scored their next drug approval with dupilumab, an antibody for the treatment of atopic dermatitis. With three placebo-controlled clinical trials enrolling a total of 2119 adult participants, Sanofi and its partner Regeneron were able to convince the FDA of their new biological for the treatment of atopic dermatitis. The product of this expansive effort comes […]

March 29, 2017 - 3 minutesmins - By Melanie De Almeida

Best in Biotech 8 Mar 2017

Which European Blockbusters Topped the Charts in 2016?

Blockbuster drugs are raking in billions each year in sales. Let’s have a look at the top 7 European best-seller drugs of 2016 and what their competition has to say. Not surprisingly, the top 3 best-selling drugs in Europe are biologicals, which are revolutionizing the treatment possibilities for a range of conditions, from cancer to chronic diseases. But with the increasing […]

March 8, 2017 - 4 minutesmins - By Melanie De Almeida

News and Trends 23 Dec 2016

The 8 Biggest Biotech Medical Fails of 2016 in Europe

Although 2016 has brought plenty of good news in medical advances, biotech is an industry where failure is part of the game. Here’s a list of medical fails in biotech to learn from this year. Unfortunately, 2016 has not been a good year for pharma, with revenues in the top companies falling, the lowest number […]

December 23, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

Sanofi regeneron rheumatoid arthritis salurimab

News and Trends 31 Oct 2016

UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug

Sanofi and Regeneron (NY, US) have ruled their phase III clinical trial immunotherapy Sarilumab a huge success. Now awaiting US FDA and EMA approval, the results from the latest study were presented at the American College of Rheumatology (ACR) annual meeting in San Francisco. Should Sarilumab be approved, this immunotherapy will be used to treat […]

October 31, 2016 - 3 minutesmins - By Dani Bancroft

regeneron sanofi praulant odyssey alirocumab cardiac statins

News and Trends 27 Nov 2015

18,000 Patients Enrolled for One of the Most Comprehensive Trials Against Cholesterol

Sanofi & Regeneron have completed enrollment in the global Phase III for Praulent (alirocumab), which is evaluating its potential cardiovascular benefits for patients with acute coronary syndrome (ACS). The ‘Odyssey Outcomes’ Study has enrolled around 18,000 patients for its trial (phwoar), and if it shows positive results could be a huge success for Sanofi and […]

November 27, 2015 - 2 minutesmins - By Dani Bancroft

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Regeneron

Update: Fifth US Antibody Patent Owned by UK Biotech Upheld in Regeneron Battle

Finnish Genetics Study Provides Clues for Treating Type 2 Diabetes

Dutch and US Biotechs Team Up Against HPV-related Cancer

Biotech and Pharma Giants Make a Good Start to Phase II Trial for Skin Cancer

Update: The EU Approval of Dupixent Might Bring its Pricing Polemic to Europe

Checkpoint Inhibitor from Regeneron and Sanofi gets Priority After Breakup

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

Get Ready for One of the Biggest New Drug Approvals of the Year

Which European Blockbusters Topped the Charts in 2016?

The 8 Biggest Biotech Medical Fails of 2016 in Europe

UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug

18,000 Patients Enrolled for One of the Most Comprehensive Trials Against Cholesterol

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!